POZEN Reports Fourth Quarter and Year End 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
POZEN (POZN) Tops Q4 EPS by 4c; Updates on FDA CRL
March 9, 2015 7:36 AM EDTPOZEN (NASDAQ: POZN) reported Q4 EPS of $0.21, $0.04 better than the analyst estimate of $0.17. Revenue for the quarter came in at $9.9 million versus the consensus estimate of $9.5 million.
Regulatory and Commercial Update
The Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 25, 2014 and on December 16, 2014 stating that satisfactory resolution of... More
